Cre-ESCs Gene Editing
Cre-ESCs Gene Editing technology is an advanced genetic engineering platform. Bypass complex breeding, using Cyagen’s proprietary TurboKnockout® technology, our Cre-ESCs platform delivers 99.9% chimerism in Founder (F0) mice and achieves one-step acquisition of cKO/cKI homozygotes.
Dramatically Shorter Cycle
Reduce the delivery cycle to just 4-5 months, saving research time.
One-Step Homozygosity
One-step acquisition of 99.9% chimeric cKI/cKO homozygotes.
TurboKnockout® Reliability
TurboKnockout®-based, off-target-free, IP-safe, and large-fragment-ready.
Technology
Validation
FAQs
How Cre-ESCs Works
Cre-ESCs technology is an advanced genetic engineering platform that enables the rapid and reliable
generation of tissue-specific conditional knockout (cKO) or knock-in (cKI) mouse models. By introducing
loxP-flanked alleles directly into pre-validated Cre-expressing embryonic stem cells, homozygous Cre/loxP
models can be obtained in a single step, eliminating time-consuming breeding processes.
Workflow
TurboKnockout based Cre-ESCs:
Comparison
| Evaluation Dimension | TurboKnockout based-Cre-ESCs | Conventional ESCs | CRISPR/Cas9 |
|---|---|---|---|
| 99.9% Chimerism in F0/ One-step Acquisition of cKO/cKI Homozygote | Supported | Not Supported | Not Supported |
| cKO/cKI Model Delivery Cycle | 4-5 months | 14 months | 13 months |
| Patent Disputes | No | No | Potential Risks |
| Large-fragment Adaptability | Excellent | Excellent | Poor |
| Off-target Risk | Negligible | Negligible | Exist |
| Chromosome Conflict | No | Yes (Cre/loxP cannot coexist on one chromosome through breeding) | Yes (Cre/loxP cannot coexist on one chromosome through breeding) |
Rigorous QC Standards
We insure the reliability of every model through a comprehensive QC process established for our
Cre-ES cell lines:
Karyotype Analysis
To ensure chromosomal stability.
Sterility & Mycoplasma Detection
To guarantee clean cell lines.
Sex Identification & Cre PCR
To verify genotype accuracy.
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.